Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Tesaglitazar
Другие языки:

Tesaglitazar

Подписчиков: 0, рейтинг: 0
Tesaglitazar
Tesaglitazar free acid.png
Clinical data
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
  • (2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)
    ethoxy]phenyl]propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.201.079
Chemical and physical data
Formula C20H24O6S
Molar mass 392.47 g·mol−1
3D model (JSmol)
  • CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
  • InChI=1S/C20H24O6S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1 ☒N
  • Key:CXGTZJYQWSUFET-IBGZPJMESA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.

The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued further development.

Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARγ coactivator 1-α (PPARGC1A, PGC1α) and sirtuin 1 (SIRT1).


Новое сообщение